Compound class:
Synthetic organic
Comment: eAmSPC 2593 is the lead from a new class of N-ethylene linked aminomethyl spectinomycins (eAmSPCs), discovered following modification of spectinomycin, and with promising antimycobacterial activity [2]. The structure is claimed in patent WO2015048692A1 filed by St. Jude Children's Research Hospital [1].
|
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
eAmSPCs inhibit protein synthesis via the same mechanism as spectinomycin, by binding helix 34 of the 16S rRNA of the bacterial 30S ribosomal subunit [2]. |